Deutsche Bank AG Has $8.76 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Deutsche Bank AG increased its stake in Kiniksa Pharmaceuticals by 177.1%, acquiring an additional 252,125 shares for a total of 394,522 shares valued at approximately $8.76 million.
• Brokerage firms have issued positive ratings for Kiniksa Pharmaceuticals, with Wells Fargo raising their price target from $30.00 to $42.00 and Jefferies increasing theirs from $45.00 to $54.00.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share for the last quarter, surpassing analyst expectations of $0.18, with total revenue of $156.80 million.

Deutsche Bank AG raised its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 177.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 394,522 shares of the company's stock after acquiring an additional 252,125 shares during the period. Deutsche Bank AG owned about 0.54% of Kiniksa Pharmaceuticals International worth $8,762,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after purchasing an additional 9,654 shares during the period. Wells Fargo & Company MN increased its position in shares of Kiniksa Pharmaceuticals International by 54.7% during the fourth quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after purchasing an additional 7,463 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $3,955,000. Barclays PLC increased its position in shares of Kiniksa Pharmaceuticals International by 11.2% during the fourth quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after purchasing an additional 7,267 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Kiniksa Pharmaceuticals International by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Trading Up 0.2%

KNSA stock traded up $0.06 during trading on Wednesday, hitting $33.21. The company had a trading volume of 396,690 shares, compared to its average volume of 707,887. The company has a fifty day moving average price of $29.55 and a two-hundred day moving average price of $25.29. The company has a market cap of $2.46 billion, a P/E ratio of 830.46 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $34.55.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research reports. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of "Buy" and an average target price of $41.17.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, insider Ross Moat sold 27,594 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total value of $800,777.88. Following the transaction, the insider owned 9,415 shares of the company's stock, valued at approximately $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This represents a 86.18% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 679,686 shares of company stock valued at $21,274,787. Insiders own 53.48% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.